Variable versus constant frequency deep brain stimulation in patients with advanced Parkinson’s disease: study protocol for a randomized controlled trial

CURRENT STATUS: ACCEPTED

Fumin Jia
Tsinghua University

Jianguo Zhang
Beijing Tiantan Hospital

Huimin Wang
Beijing Tiantan Hospital

Zhanhua Liang
Dalian Medical University

Weiguo Liu
Nanjing Brain Hospital

Xuelian Wang
Xi'an Tangdu Hospital of No4 Military Medical University

Yiming Liu
Shandong University Qilu Hospital

Yi Guo
Peking Union Medical College Hospital

Zhipei Ling
Military General Hospital of Beijing PLA

Xiaodong Cai
Shenzhen Second People's Hospital

Xi Wu
Changhai Hospital
Jianjun Wu
Huashan Hospital Fudan University

Wen Lv
Zhejiang University School of Medicine Sir Run Run Shaw Hospital

Xin Xu
military general hospital of beijing PLA

Wenbin Zhang
Nanjing Brain Hospital

Luming Li
Tsinghua University

Corresponding Author
lilm@tsinghua.edu.cn

DOI:
10.21203/rs.2.9658/v3

SUBJECT AREAS
Translational Medicine

KEYWORDS
Parkinson’s disease, Deep brain stimulation, Variable frequency stimulation, Subthalamic nucleus
Abstract

Background: Deep brain stimulation (DBS) targeting the subthalamic nucleus (STN) can be used to treat motor symptoms and dyskinesia in the advanced stages of Parkinson’s disease (PD). High frequency stimulation (HFS) of the STN can lead to consistent, long-term improvement of PD symptoms. However, the effects of HFS on the axial symptoms of PD, specifically freezing of gait (FOG), can be limited or cause further impairment. While this can be alleviated via relatively low frequency stimulation (LFS) in select patients, LFS does not control all motor symptoms of PD. Recently, the National Engineering Laboratory for Neuromodulation reported preliminary findings regarding an efficient way to combine the advantages of HFS and LFS to form variable frequency stimulation (VFS). However, this novel therapeutic strategy has not been formally tested in a randomized trial.

Methods/Design: We propose a multicenter, double blind clinical trial involving 12 study hospitals and an established DBS team. The participants will be divided into a VFS and a constant frequency stimulation (CFS) group. The primary outcome will be changes in Stand-Walk-Sit (SWS) task scores at three months of treatment in the “medication off” condition. Secondary outcome measures include specific item scores on the Freezing of Gait Questionnaire and quality of life. The aim of this trial is to investigate the efficacy and safety of VFS compared with CFS.

Discussion: This is the first randomized controlled trial to comprehensively evaluate the effectiveness and safety of VFS of the STN in patients with advanced PD. VFS may represent a new option for clinical treatment of PD in the future.

Trial registration: The present protocol is registered at ClinicalTrials.gov: NCT03053726.

Background

Deep brain stimulation (DBS) of the subthalamic nucleus (STN) is an established treatment for Parkinson’s disease (PD). However, debilitating axial symptoms such as gait impairment, postural instability, postural abnormalities, dysphagia, and dysarthria are frequently observed in individuals with advanced PD [1]. Axial motor impairments can be highly debilitating, and are a common cause of disability in patients with PD. Freezing of gait (FOG) is a unique and disabiling clinical phenomenon
that typically occurs when initiating gait or when turning while walking. It is characterized by brief episodes in which the patient demonstrates an inability to step, or makes repeated use of extremely short steps [2]. The inability to start walking is a prominent feature in PD patients with FOG. However, once this so-called ‘freezing’ pattern is interrupted, patients often regain the ability to walk normally [3]. FOG has also been observed in patients with progressive supranuclear ophthalmoplegia, multiple system atrophy, corticobasal degeneration, and numerous other diseases [4]. Additional axial signs include postural instability and changes in postural alignment, such as camptocormia or Pisa syndrome. Dysphagia and speech disorders, especially dysarthria and stuttering, are equally disabling axial motor features. However, conventional DBS stimulation has limited therapeutic potential for treating these symptoms. Thus, these symptoms represent a public health issue for which a specific treatment is currently lacking.

High-frequency DBS of the STN (STN-HFS) mainly improves levodopa-sensitive PD symptoms. However, it is typically less effective in improving axial symptoms, such as FOG [5]. Previous studies have shown that subthalamic stimulation with low frequency (STN-LFS) improves axial motor activity in some PD patients, but with short-term therapeutic efficacy. Thereafter, patients may present with increased tremor, rigidity, and bradykinesia, and the intensity of symptoms often outweighs the initial benefits of LFS therapy for FOG [6, 7]. The conventional HFS or LFS programming is called constant frequency stimulation (CFS), due to the fixed stimulation frequency, which is the current standard method of deep brain stimulation. Previously, we successfully used variable frequency stimulation (VFS) of the STN to treat FOG in PD patients [8]. Further, we recently conducted a study with 28 participants (under review) that revealed that, compared with HFS and LFS, VFS DBS improved FOG and appendicular motor symptoms in PD patients with sustained benefits for 12 months. Our pilot study suggested that VFS composed of both HFS and LFS was safe, and we did not observe any clinically relevant neuropsychiatric adverse effects. To the best of our knowledge, no controlled prospective studies have compared VFS with CFS in patients with PD. To this end, we designed a prospective, controlled study investigating the outcome of VFS in patients with advanced PD.

Aims
The motives for this clinical study are twofold. First, we plan to evaluate the short-term effects of VFS and CFS on motor and axial symptoms in patients with advanced PD. Second, we hope to gain insight regarding whether VFS is more effective than CFS after 3 months of treatment, with a 6-month follow-up period. The study has a randomized double-blind design.

Design And Methods

**Trial design**

The RESTEP Study (ClinicalTrials.gov ID: NCT03053726) is a double blind, randomized, multicenter trial designed to evaluate the safety and effectiveness of STN-VFS treatment in participants with advanced PD. According to the trial flow chart (Figure 1), participants with advanced PD who had previously undergone DBS will be screened based on strict inclusion and exclusion criteria. A total of five follow-up surveys will be scheduled as shown in Table 1. After recruitment, pulse generators previously implanted in all participants will be upgraded from those with a single mode (CFS only) to those that are capable of dual mode stimulation (CFS or VFS). Following this upgrade, participants will be randomly and equally divided into two groups, the CFS group and the VFS group. After 3 months of stimulation in the blinded conditions, all participants will receive VFS and follow-up assessments for 6 months. The protocol design is based on the guidelines of the Consolidated Standards of Reporting Trials (CONSORT) and Standard Protocol Items: Recommendations for Interventional Trials (SPIRIT), and the study results will also be reported according to these guidelines. Informed consent will be obtained from all participants in accordance with the policies of the board.

**Trial population**

The trial will be conducted in approximately 11 centers. These include Beijing Tiantan Hospital, the first affiliated hospital of Dalian medical university, Nanjing brain hospital, Tangdu Hospital (Fourth Military Medical University of Chinese PLA), Qilu Hospital, Peking union medical college hospital, Chinese PLA general hospital, the second people’s hospital of Shenzhen, Changhai hospital of Shanghai, Huashan hospital, Sir Run Run Shaw Hospital (Affiliated with School of Medicine, Zhejiang University). Other hospitals will be invited to join the study according to interest, feasibility, and resources. The clinical investigators from each center will be responsible for screening eligible
Patient population and recruitment

We intend to enroll a total of 106 participants aged over 18 years. The prospective cohort will comprise PD patients who have received STN-DBS treatment and have implanted impulse generators that are compatible with VFS (PINS Medical).

Inclusion criteria

1. Patients with idiopathic Parkinson’s disease
2. Aged ≥ 18 years, both male and female
3. Patients who have already undergone DBS and currently have an implanted STN-DBS stimulator
4. A Mini-Mental State Examination (MMSE) score of ≥ 24
5. A Hoehn-Yahr (H-Y) score of ≥ 2.0 when undergoing CFS in a “medication off” state
6. A score of ≥ 1 on the 14-item Unified Parkinson’s Disease Rating Scale II (UPDRS-II)
7. A score of ≥ 2 on the 15-item UPDRS-II
8. The ability to walk ≥ 10 meters independently when receiving CFS in a “medication off” state

Exclusion criteria

1. Pregnant women, breastfeeding mothers, or woman who are unable to take effective measures to prevent pregnancy
2. Presence of other diseases that can affect walking distance, such as joint disease in the lower body, spinal disease, neuropathy, or serious heart or lung disease
3. Serious health conditions such as tumor, liver or kidney disease, etc.
4. Epilepsy or other seizure disorders
5. Mental disorders or dementia
6. Inability to comprehend the experimental protocol or voluntarily provide informed
7. Lack of cooperation with follow-up requirements

8. Additional reasons for exclusion at the discretion of the clinical investigator

Recruitment of participants
Participants will be recruited by placing advertisements on social media and posters in clinics and directly at the participating centers. The recruitment information mainly includes eligibility criteria and contact details. A well-trained investigator in each participating center will be responsible for screening all potentially eligible patients based on the eligibility criteria and obtaining the informed consent.

Interventions
Constant Frequency Stimulation (CFS)
To deliver CFS, electrical stimulation will be set to a constant frequency by the physician programming the stimulation frequency parameters, i.e., the pulse width and amplitude. The participants with receive STN-DBS with single frequency, single pulse width, and single amplitude stimulation.

Variable Frequency Stimulation (VFS)
The VFS parameters will be selected based on previous findings regarding the relationship between stimulation frequency and movement rhythm regulation in humans. The stimulation frequency will be set to alternate between high and low frequencies.

Concomitant interventions
Participants will be allowed to continue taking medications they had been on before the trial. Use of all drugs, if any, will be documented in the Case Report Form (CRF).

Randomization and blinding
Eligible participants will be randomly assigned to one of two groups (CFS group or VFS group) after completing the baseline measurements. A 1:1 assignment sequence (based on computer-generated random numbers) will be produced by The Peking University Clinical Research Institute. The
computer-generated random numbers will be used to create the participant numbers and order lists, which will be placed in opaque sealed envelopes and sent to the research centers. The research clerk will keep copies of the order lists and participant numbers.

Throughout the study, with the exception of the study programmer, all participants and study staff (including investigators, trainers, and statisticians) will be blinded to the treatment allocation. Independent raters who have no therapeutic relationships with the participants and who are blind to the treatment conditions will conduct outcome assessments. The independent raters will be clinical neurologists who have received additional training on the use of the outcome assessments, had the opportunity to listen to conducted assessments, and received direct feedback regarding their assessments from supervisors. Further, the Data and Safety Monitoring Board will review a random selection of 20% of the recorded assessments. Loss of blinding may occur due to the magnitude of the therapeutic effect or any other subjective perception that indicates that VFS or CFS is delivered.

**Trial outcomes**

**Primary clinical outcomes**

The primary outcome will be Stand-Walk-Sit (SWS) task scores at 3 months compared with the baseline scores. The domain of the SWS score is the gait. The study will compare the mean scores in each group between 3 months and baseline, use the mean scores from each group. The SWS test is a simple and quick functional mobility test that requires an individual to stand up, walk 5 m, turn, walk back, and sit down. The time taken to complete the test is strongly correlated with the level of functional mobility. This test will be videotaped and scored by two blinded neurologists.

**Secondary clinical outcomes**

As secondary outcomes, we will use the Freezing of Gait Questionnaire (FOGQ), Gait and Falls Questionnaire (GAFQ), and Parkinson’s Disease Quality of Life questionnaire (PDQ–39), as well as total UPDRS and UPDRS III scores to assess PD symptom severity at 3 and 6 months compared with the baseline. These questionnaires assess physiological symptoms and emotional function in PD patients. Participants in both trial groups will be asked to complete these questionnaires at baseline and post-treatment, and the trial group will also be asked to complete the measures 3-months and 6-months
post-treatment. The study will compare the mean change scores from baseline at each time point, use the mean scores from each group.

Safety aspects

Adverse Events

An adverse event (AE) could include an abnormal laboratory finding, symptom, or disease temporally associated with the administration of an investigational product, regardless of whether it is related to that investigational product. In the present study, an unexpected AE is anything that is not identified in nature, severity, or frequency in the Investigator’s Brochure. During routine assessments, the investigator will questions the participants about the occurrence of AEs and record the information in the source documents and patient case report form (CRF).

Serious Adverse Events (SAEs)

Death
A life-threatening adverse experience
Inpatient hospitalization or prolongation of existing hospitalization
A persistent or significant disability/incapacity
A congenital anomaly/birth defect

Other important medical events may also be considered SAEs when, based on appropriate medical judgment, they jeopardize the participant or require intervention to prevent one of the outcomes listed.

When AEs occur throughout the clinical trial, investigators may take necessary measures according to the condition of the participant. Based on the severity of the AE, the investigators may choose hospitalization, outpatient treatment, home visits, communication, or other follow-up methods.

Data and Safety Monitoring Board (DSMB)

The DSMB will review the safety, ethics, and outcomes of the study. It is independent from the sponsor and has no competing interests. DSMB members will monitor blinded assessment data for SAEs or potential harmful effects. A charter that will outline member responsibilities, procedures, and confidentiality will govern the DSMB. The DSMB will also review unblinded data at regular intervals during the follow-up period and will monitor neurological and functional differences between the two groups, as well as dropout and event rates. Furthermore, the DSMB members will also manage the
oversight of the trial progress, such as the status of recruitment and involvement of the sites.

**Data quality and management**

Data collection will be restricted to the those meet the eligibility criteria. Participants who withdraw from the study for any reason will be recorded in their medical records and reviewed by the trial monitor.

**Data collection and monitoring**

1. CRFs must be completed according to the schedule.
2. All SAEs that occur during the observation period must be reported to the medical expert overseeing the investigation, i.e., the medical director of Beijing PINS Medical Co., Ltd.
3. The investigators are responsible for all information collected about participants enrolled in this study. The investigators and sponsor will conduct regular telephone or home follow-up of patients.
4. The monitoring system will assure the quality of the assessments.
5. The data will be entered into a validated database.
6. The Data Management Group will be responsible for data processing, in accordance with procedural documentation. The database will be locked once quality assurance procedures have been completed.

**Withdrawal and terminate from the study**

In case of endangerment of personal safety, lack of compliance, or withdrawal of informed consent, a patient will instantly be excluded from the study. Further, participants will be withdrawn from the study in the following conditions: (1) The patient’s parents require withdrawal; (2) The patient develops heart failure, respiratory failure, or another serious disease. The DSMB might terminate the study in the following conditions: (1) SAEs occurred during the trial, the investigator determined that the trial should be terminated; (2) The Ethics Committee require.

**Handling of Missing Data**
All variables included in the CRF are mandatory. The method last visit carried forward will be used to handle the missing data.

**Data auditing**

This trial will be audited by the Research Ethics Committee and the China Food and Drug Administration. The audits will be performed when the first participant enrollment, half and all of the enrolled cases are completed.

**Statistical considerations**

**Sample size**

The sample size was calculated based on the primary outcome measure according to the results of our pilot study. Power was set at 80% and calculated based on two-sided 95% confidence intervals. In our pilot data, we detected a post-treatment difference in PD symptoms of at least 20% between the VFS and CFS groups of SWS scores. We assume that the placebo effect can account for about 10% of such differences. The sample size in each group was determined using a formula derived by Whitley et al. We assume that 10% of the trial participants will be lost to attrition. Thus, 53 participants need to be allocated to each treatment group to establish a difference among the treatments at a level of 5% with a power value of 90%.

**Data analysis**

All evaluations of effectiveness and safety will be conducted according to the intention-to-treat (ITT) principle. The final data will be analyzed using IBM SPSS 13.0 or higher (SPSS, Inc., Chicago, IL, USA) and SAS 9.4 or higher (SAS Institute Inc., Cary, NC, USA) software. A p-value < 0.05 will be considered statistically significant. Data will be analyzed with t-tests and χ² tests for continuous variables and categorical variables, respectively.

**Confidentiality**

When participating in research there is always a risk regarding the confidentiality of information. All information gathered in the present study will be stored in a secure database. All participants will provide written informed consent prior to being assessed for eligibility for inclusion in any part of the study. Every precaution will be taken to respect the privacy of participants in the conduct of the
study. Information will be stored on a password-protected server with access that is limited to members of the study team. In the course of monitoring data quality and adherence to the study protocol, the monitors will refer to medical records at the participating hospitals. All individual and site information will be de-identified when reporting the data and results to protect the confidentiality of the participants.

Discussion
Axial and appendicular motor symptoms severely affect quality of life in PD patients. DBS is an effective well-established therapy for medication-refractory PD patients. High-frequency DBS is highly efficacious in ameliorating appendicular symptoms in PD patients, but less effective in improving axial symptoms, especially on a long-term basis [5]. New conceptions of DBS have focused on the use of LFS or combined STN/SNr-DBS for the treatment of axial symptoms in PD patients [6, 9, 10]. LFS may help improve postural control as well as gait, particularly in PD patients who do not develop gait-related disorders after HFS [11]. However, the beneficial effects of LFS on axial symptoms remain controversial [12]. Therefore, the development of novel approaches to managing both axial and appendicular motor symptoms in PD patients is critical. Based on these findings and our previously published case report [8], we hypothesize that PD patients with FOG might benefit from STN-VFS. This multicenter double-blind randomized clinical trial will enable us to evaluate the effect of a novel STN-VFS stimulation pattern on both axial and segmental symptoms of PD. This study was designed to evaluate the short-term effects and potential side effects of VFS and CFS on axial symptoms in advanced PD. We hope to gain insight regarding whether VFS or CFS is more effective for treating axial symptoms of PD. This study has several strengths. First, group-assignment in the double-blinded phase was randomized. Second, we performed a power calculation for this study. Most important of all, this new paradigm possibly offer an approach that could optimal DBS programming and improve PD DBS outcomes. At present, the total number of patients enrolled in the study is 50.

Trial Status
The trial is ongoing and is actively enrolling. The protocol version 1.1, PINS-VFS-1601, 11/10/2016. The trial will be ongoing from August 2017 to December 2019.

Abbreviations
SPIRIT, Standard Protocol Items: Recommendations for Interventional Trials; CONSORT, Consolidating Standards of Reporting Trials; DBS, deep brain stimulation; STN, subthalamic nucleus; HFS, high frequency stimulation; LFS, low frequency stimulation; VFS, variable frequency stimulation; CFS, constant frequency stimulation; RCT, randomized controlled trial; DSMB, Data and Safety Monitoring Board; PD, Parkinson’s disease; FOG, freezing of gait; SWS, Stand-Walk-Sit; MMSE, Mini Mental Status Examination; UPDRS, Unified Parkinson’s Disease Rating Scale; PDQ–39, Parkinson’s Disease Questionnaire for quality of life; CRF, case report form; FOGQ, Freezing of Gait Questionnaire; AE, adverse event; SAEs, serious adverse events; ITT, intention-to-treat; EG, experimental group; CG, control group.

Declarations

Acknowledgements

We would like to thank the entire team of researchers, including the nurses and staff at all 11 hospitals, for their determination, professional skills, enthusiasm, and effort.

Funding

This study was supported by National Key Development Plan of China (Grants no. 2016YFC0105900) and National Natural Science Foundation of China (Grants no. 81701120). Funding 2016YFC0105900 is responsible for the study organization and conduct. Funding 81701120 is responsible for the study design, meeting and transportation.

Availability of data and material

Data from this randomized controlled study are unavailable at the time of publication. Individual participant data is available upon request.

Author contributions

Conception and design: FMJ, LML; Study coordination: FMJ, JGZ; Acquisition of legal authorization and datas: JGZ, HMW, ZHL, WGL, XLW, YML, YG, ZPL, XDC, XW, JJW, WL, XX, WBZ; Drafting and writing of the manuscript: FMJ; Revision the approval of the final version of the manuscript: LML; All authors reviewed and approved the final version of the manuscript.

Ethics, consent, and participants
The study will be conducted according to the Good Clinical Practice Guidelines and the principles of the Declaration of Helsinki. Written informed consent will be obtained from each participant. The study protocol was approved by the Medical Ethics Committee Board of every center. To make any amendments to the protocol (Protocol Number: PINS-VFS–1601; Date: 10/11/2016), approval will be sought from the Institutional Review Board of Tiantan hospital. Informed consent must be provided in standard writing, the investigators elaborate the content to the participants. Informed consent will be provided by all participants, including their consent regarding the publication of the results to the investigators. Confidentiality will be ensured during all handling of the data. This study has been approved by Ethics Committee of Beijing Tian Hospital, Capital Medical University (number, QX2016-015-02).

Consent for publication

Not applicable.

Competing interests

The authors declared that they have no competing interests.

References

1. Fasano A, Aquino CC, Krauss JK, Honey CR, Bloem BR: Axial disability and deep brain stimulation in patients with Parkinson disease. Nat Rev Neurol 2015, 11(2): 98–110.

2. Fahn S: The freezing phenomenon in parkinsonism. Adv Neurol 1995, 67: 53–63.

3. Shine JM, Naismith SL, Lewis SJ: The pathophysiological mechanisms underlying freezing of gait in Parkinson’s Disease. J Clin Neurosci 2011, 18(9): 1154–1157.

4. Nutt JG, Bloem BR, Giladi N, Hallett M, Horak FB, Nieuwboer A: Freezing of gait: moving forward on a mysterious clinical phenomenon. Lancet Neurol 2011, 10(8): 734–744.

5. Benabid AL, Chabardes S, Mitrofanis J, Pollak P: Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease. Lancet Neurol 2009, 8(1): 67–81.

6. Sidiropoulos C: Low-frequency stimulation of STN-DBS reduces aspiration and freezing of gait in patients with PD. Neurology 2015, 85(6): 557.

7. Zibetti M, Moro E, Krishna V, Sammartino F, Picillo M, Munhoz RP, et al: Low-frequency Subthalamic
Stimulation in Parkinson’s Disease: Long-term Outcome and Predictors. Brain Stimul 2016, 9(5):774-779.

8. Jia F, Guo Y, Wan S, et al: Variable frequency stimulation of subthalamic nucleus for freezing of gait in Parkinson’s disease. Parkinsonism Relat Disorders 2015, 21(12): 1471-1472.

9. Weiss D, Walach M, Meisner C, Fritz M, Scholten M, Breit S, et al: Nigral stimulation for resistant axial motor impairment in Parkinson’s disease? A randomized controlled trial. Brain 2013, 136(7):2098-2108.

10. Weiss D, Breit S, Wächter T, Plewnia C, Gharabaghi A, Krüger R: Combined stimulation of the substantia nigra pars reticulata and the subthalamic nucleus is effective in hypokinetic gait disturbance in Parkinson’s disease. J Neurol 2011, 258(6):1183-1185.

11. Vallabhajosula S, Haq IU, Hwynn N, Oyama G, Okun M, Tillman MD, et al: Low-frequency versus high-frequency subthalamic nucleus deep brain stimulation on postural control and gait in Parkinson’s disease: a quantitative study. Brain Stimul 2015, 8(1):64-75.

12 Sidiropoulos C, Walsh R, Meaney C, Poon YY, Fallis M, Moro E: Low-frequency subthalamic nucleus deep brain stimulation for axial symptoms in advanced Parkinson’s disease. J Neurol 2013, 260(9):2306-2311.

Tables
Table 1. Detailed schedule of the RESTEP trial
| Schedule | Baseline | Visit | Time | Follow-up |
|----------|----------|-------|------|-----------|
|          | Screening | Upgrading | EG for VFS | CG for CFS | EG for VFS | CG for VFS | EG for VFS | CG for VFS | EG for VFS | CG for VFS |
|          | 3±2 days  | 5±2 days | 90±14 days | 90±14 days | 90±14 days |
| Informed consent | X | | | | | |
| Criteria for inclusion | X | | | | | |
| Criteria for exclusion | X | | | | | |
| MMSE | X | | | | | X |
| Hoehn-Yahr staging | X | | | | | |
| Medical history/demographic data | X | | | | | |
| Physical examination | X | | | | | |
| Records of side effects | X | X | X | | | |
| PDQ-39 | X | | | | | X |
| FOG-Q | X | | | | | |
| GAFQ | X | | | | | X |
| Medication | X | | | | | X |
| UPDRS (Part I/II/IV) | X | | | | | |
| Upgrade to dual mode | X | | | | | |
| Random grouping | X | | | | | |
| Programming | X | X | X | X | X | |
| SWS-Test | X | X | | | | X |
| UPDRS (Part III) | X | X | | | X | |
| Admission confirmed | X | | | | | |
| AE | X | X | | | X | |
| SAE | X | X | | | X | |

Figures
Figure 1
Flow chart of the RESTEP trial

Supplementary Files
This is a list of supplementary files associated with this preprint. Click to download.
SPIRIT_Fillable-checklist.pdf